SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Dulaglutide

Cat. No.: HY-P0120
CAS No.: 923950-08-7
Target: GCGR
Pathway: GPCR/G Protein
Storage: Store at 4°C, do not freeze

Dulaglutide

BIOLOGICAL ACTIVITY

Description	Dulaglutide (LY2189265) is a glucagon-like peptide-1 (GLP-1) receptor agonist. Dulaglutide can be uesd for the research of type 2 diabetes (T2D) [1][2].
IC_{50} & Target	GLP-1 receptor[1]

In Vitro

Dulaglutide (50 nM and 100 nM; 24 h) ameliorates ox-LDL-induced oxidative stress and suppresses ox-LDL-induced mitochondrial dysfunction in human aortic endothelial cells (HAECs)[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line:	Human aortic endothelial cells (HAECs)
Concentration:	50 nM, 100 nM
Incubation Time:	24 hous
Result:	Suppressed ox-LDL-induced reduction of cell viability and release of lactate dehydrogenase (LDH).

In Vivo

Dulaglutide (0, 0.05, 0.5, 1.5, or 5 mg/kg; s.c.; twice week, for 93 weeks) increases the incidence of thyroid C-cell hyperplasia and neoplasia in the rat carcinogenicity study[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Rats and Transgenic mice[1]
Dosage:	0, 0.05, 0.5, 1.5, or 5 mg/kg; 0, 0.3, 1, or 3 mg/kg
Administration:	SC, twice week, for 93 weeks; SC, twice week, for 26 weeks
Result:	Statistically increased diffuse C-cell hyperplasia and adenomas at ≥0.5 mg/kg. Decreased Systemic exposures over time in mice.

CUSTOMER VALIDATION

- J Clin Endocrinol Metab. 2022 Feb 9.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Hertzel C Gerstein, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet

[2]. Chang W, et al. Glucagon-like peptide-1 receptor agonist dulaglutide prevents ox-LDL-induced adhesion of monocytes to human endothelial cells: An implication in the treatment of atherosclerosis. Mol Immunol. 2019 Dec;116:73-79.

[3]. Byrd RA, et al. Chronic Toxicity and Carcinogenicity Studies of the Long-Acting GLP-1 Receptor AgonistDulaglutide in Rodents. Endocrinology. 2015 Jul;156(7):2417-28.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA